One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Issue Highlights
doi : 10.1016/S0360-3016(24)03481-3
Volume 120, Issue 5, 1 December 2024, Pages A9-A12
Honing Locoregional Therapy for Breast Cancer: Refinement of Surgical and Radiotherapeutic Management
Stick Your Neck Out: Reirradiate or Not in a Head and Neck Cancer Patient With Extracapsular Extension After Salvage Neck Dissection
Generative Artificial Intelligence: A New Frontier of Scientific Misconduct?
Caught Between a Radiation Oncology Case Rate (ROCR) and a Hard Place: Improving Proposed Radiation Oncology Alternative Payment Models
Patients’ Perceived Valorization Toward Ringing the Cancer Bell at the End of Their Radiation Therapy
Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials
Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?
The Hidden Benefits of Palliative Radiation Therapy: When Radiation of Metastatic Disease Is Not “Just� Palliative
Early-Stage Breast Cancer: A Critical Review of Current and Emerging Practice
Curative Approaches for Metaplastic Breast Cancer: A Retrospective Cohort Outcome Review
Real-World Experience in Hispanic Patients With Breast Cancer and Brain Metastases Using Different Prognostic Tools
International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal Carcinoma
PTCOG Ocular Statement: Expert Summary of Current Practices and Future Developments in Ocular Proton Therapy
An Analysis of Positron Emission Tomography Maximum Standard Uptake Value Among Patients With Head and Neck Cancer Receiving Photon and Proton Radiation
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial
Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma
Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial
Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial
Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study
Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing–Initial Report of the SABR-Dual Trial
Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy
An Additional Randomized Trial That Needs to Be Carefully Considered When Evaluating the Need for Rectal Spacer Devices
Minibeam Radiation Therapy Treatment (MBRT): Commissioning and First Clinical Implementation
Thermoradiotherapy Optimization Strategies Accounting for Hyperthermia Delivery Uncertainties
Evaluating Virtual Contrast-Enhanced Magnetic Resonance Imaging in Nasopharyngeal Carcinoma Radiation Therapy: A Retrospective Analysis for Primary Gross Tumor Delineation
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.
